Endpoints Shorts: Dr. Nadia Sethi on Biogen's Tofersen Trial for Presymptomatic Carriers

Welcome to the latest episode of Endpoints Shorts. In these bite-size podcasts, we’ll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space ­– all in 15 minutes or less.

Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI’s Director of Community Outreach and Engagement. Today, Nadia joins us to talk us through Biogen’s Tofersen Trial for presymptomatic people with SOD1 gene mutations.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.